About BioPhotonix
Bridging the gap in retinal care.
BioPhotonix is ending the era of passive observation. We are engineering the shift from monitoring disease to active, accessible intervention for the world's second leading cause of blindness.
BioPhotonix was founded on a single, uncompromising belief:
Early intervention is the only way to preserve independence.
We are building the world's first scalable, system-optimised photobiomodulation platform, converting “nothing can be done” into a structured, evidence-led clinical pathway.
Our origin
The current care pathway for dry AMD is structurally broken.
As diagnostic technology in community optometry has advanced, we are identifying retinal disease earlier than ever before. Yet for millions of patients this early diagnosis is followed by a “watch and wait” approach. Patients are monitored as their vision inevitably declines, simply because effective hospital-grade interventions are not scalable to the community setting.
We were established to close this gap. By translating the science of photobiomodulation into a regulated, portable medical platform, we are empowering optometrists to intervene early, preserving vision and independence for the ageing population.
With the global economic burden of AMD exceeding $49 billion annually and millions losing their independence, BioPhotonix is not just building a device. We are building the infrastructure for the future of global eye health.
How we work
Safety and accessibility, in that order.
We are not a wellness company. BioPhotonix is built on the principles of regulated medical technology.
Clinician-led
Powerful therapy requires expert supervision. Our technology is designed to be initiated and monitored by eye-care professionals.
Evidence-first
We prioritise clinical validation and regulatory compliance over speed to market.
Patient-centric
We measure success not just by clinical biomarkers, but by the preservation of patient independence.
Regulatory-first
A Class IIa device, an ISO 13485 quality system and a CE-first strategy. Safety is engineered in from the start, not added at the end.
Leadership
Adail Islam
Founder and Director · BSc Optometry, BSc Orthoptics
Adail is an optometrist and orthoptist with extensive clinical experience managing macular disease across both hospital ophthalmology pathways and community optometry settings.
His direct experience on the front lines of eye care revealed the limitations of existing treatments: hospital-bound technologies could not scale to meet the needs of the millions of patients managed in primary care. Adail founded BioPhotonix to engineer a solution that fits the reality of clinical practice: a device that is clinically rigorous, regulator-ready, and accessible enough to be deployed in every community clinic.
Strategic advisors and development partners
Built with world-class allies.
No medical innovation is built in isolation. Our scientific, regulatory and engineering partners keep Revolux grounded in evidence and built to standard.
Scientific and clinical advisory
Dr Nikola Krstajic
PhD, Lecturer in Medical Physics, University of Dundee
Ensures our device parameters are grounded in the latest photobiological research and retinal safety standards.
Regulatory and compliance
Edwin Lindsay
Managing Director, Compliance Solutions Life Sciences
Strategic guidance on our ISO 13485 quality management system and our UKCA and CE regulatory pathways.
Engineering partner
Martin Pacitti
Project Manager, WideBlue
Our development roadmap is executed with leading medical design houses, so Revolux is built to rigorous industrial and ergonomic standards.
Development partners
Med Design
Functional prototypes and ergonomics
Fraunhofer
Optical engineering
WideBlue
Product development
Compliance Solutions
Quality and regulatory
University of Dundee
Medical physics advisory